Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Quanterix, a developer of single molecule array technology, has closed the second tranche of its series A round, bringing the total series A financing amount to $15 million.
Subscribe to our email newsletter
Arch Venture Partners, Bain Capital Ventures, and Flagship Ventures co-led the round. Proceeds from the financing will be used to validate the platform and accelerate development of ultrasensitive assays targeting a variety of biological analytes.
Accoring to Quanterix, its single molecule array technology will bring an unprecedented level of sensitivity, precision, and assay robustness to clinical diagnostics, drug development, and life science research.
Dr Naclerio, chairman and interim CEO of Quanterix, said: “The financial support that we have received will allow us to expand our efforts to develop innovative diagnostic solutions and commercialize products that address unmet medical needs.”